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Oral Presentations S229Voriconazole was given as prophylaxis in 44% of cases, 23% re-
ceived it empirically and 33% as therapy. 14 of the 19 children
treated therapeutically had aspergillosis (11 possible, 2 probable, 1
proven). Dosing was according to the summary of product character-
istics. For children\2 yrs the recommended dosage for 2-12 yrs was
used. Voriconazole was prescribed for a mean period of 63 days
(range 6-415). In 11% of cases the drug was stopped due to toxicity.
Therapeutic drug monitoring of voriconazole: An adequate
trough level was defined as 1-5 mg/ml. First measurement of trough
levels was after a median of 5 days.
Only in 8% of children\2 years an adequate level was reached at
initial dosing.
3 of 15 children between 2-7 yrs of age on recommended dosage
had adequate levels at initial dosing (20%); in children aged 7-12
yrs 83% had adequate initial levels if dosage was as recommended.
14/33 patients.2 yrs on recommended dose had voriconazole levels
below the limit of detection (\0.5 mg/ml). 9% of all patients had an
initial trough level . 5 mg/ml.
The mean dose (range) to reach adequate trough levels for chil-
dren\2 was: 365 mg oral (220-600) and 29.4 mg/kg i.v. (5.2-70).
For the age group 2-7 years adequate levels were reached with
a mean dose of 26.2 mg/kg i.v. (20.7-29.6). .12 years this was
17.6 mg/kg i.v. (11.9-19.6).
Intrapatient variability of levels on constant dosage was 0.7-3.5
fold.
Conclusion: We conclude that therapeutic drug monitoring is in-
dispensable for correct dosage of voriconazole. Dosage recommen-
dations for children need adjustment, especially in the \2 age
group. Intra patient variability is also a major concern and necesit-
tates continued level measurements. Patient characteristics that de-
termine pharmacokinetic variability need to be identified in future
studies.
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FLUDARABINE + EXPOSURE-TARGETED BUSULFAN IN CHILDREN WITH
MALIGNANT AND NON-MALIGNANT DISEASES: AN EFFECTIVE AND LOW
TOXIC REGIMEN
Boelens, J.J.1, Bartelink, I.2, Lindemans, C.A.1, Bierings, M.1 1UMC
Utrecht, Netherlands; 2UMC Utrecht, Netherlands
Background: Busulfan (Bu) as myeloablative agent is used in condi-
tioning regimens prior to HSCT. We recently found a clear associ-
ation between Bu-exposure and outcomes. Comparison studies in
adults showed a favorable toxicity profile for fludarabine+busulfan
(FludBu) compared to the conventional BuCy regimen.We recently
initiated a prospective study analysing the effectively of FluBu inmy-
eloid malignancies and all non-malignant indications in pediatrics.
We compared the outcomes with our Bu(-exposure targeted)/Cy/
(Mel) from a previous cohort (2005-2008).
Methods: Fludarabine 40mg/m2 was given in 1 hour prior to a 3
hour infusion of once daily busulfan. The target area under the curve
(AUC) for Bu was 75-95 mg*h/L (in total) in both groups. Bu dose
targeting, based on therapeutic drug monitoring was performed be-
fore the second dose. Primary endpoint was event free survival (EFS)
and survival. Secondary endpoints were acute graft-versus-host dis-
ease (aGvHD), neutropenic period and the number of erythrocytes
and thrombocytes transfusions. A risk factor analysis was performed
using univariable and multivariable COX regression.
Results: 100 patients were included: 65 unrelated-CBT, 22 a MSD
and 13 a MUD. 52 patients were included in the FludBu group (me-
dian follow up 244 days; range 22-769) and 48 in the BuCy(Mel)
group (1015 days; range 6-2085). The median exposure of busulfan
was 88 (81-94)mg*h/L inFluBu and82 (74-100)mg*h/L inBuCy(Mel).
The groups were comparable regarding age, cell source, gender, in-
dication for BMT and match-grade. The probability on EFS in
FludBu and BuCy(Mel) was 74+/-6% and. 70+/-7% (NS), resp.
No difference in aGvHD ($grade 2: 20 vs.28%) was found. A trend
to a lower ‘‘non-relapse mortality’’ was found in the FluBu group
7+/-4% vs. 19+/-6% (p 5 0.08). The period of neutropenia was
median 11 in the FludBu compared to 20.5 in BuCy(Mel) (HR
0.38, p 5 0.05, CI95% 0.20-0.75). The median number of erythro-
cytes transfusion was 1 (range 1-13) in the FludBu group and 5 (0-22)
in the BuCy(Mel) group (p 5 0.02) and thrombocyte transfusions
4 (range 0-33) vs 10 (range 2-44; p 5 0,02). Less VOD was seen in
BuFlu 3% vs. 22% (p 5 0.01).Conclusion: Bu with a total target AUC of 75-95mg*h/l in combi-
nation with Flud showed to be an effective and low toxic regimen in
comparison to BuCy(Mel). A shorter neutropenic period and a lower
number of transfusions were needed in FludBu. FludBu as reduced
toxicity regimen showed promising results.72
UNRELATED BONE MARROW TRANSPLANTATION (UBMT) FOR CHIL-
DREN AND ADOLESCENTS WITH FANCONI ANEMIA (FA) USING CYCLO-
PHOPHAMIDE, FLUDARABINE AND RABBIT ATG: ANALYSIS OF 33
PATIENTS TRANSPLANTED AT A SINGLE INSTITUTION
Bonfim, C., Ribeiro, L., Loth, G., Bitencourt, M., Kanaan, S.N.,
Koliski, A., Funke, V., Pilonetto, D., Zanis-Neto, J., Pasquini, R. Federal
University of Parana, Curitiba, PR, Brazil
FA is a rare disease characterized by progressive bonemarrow fail-
ure, congenital anomalies and a striking predisposition to cancer.
HSCT is the only treatment able to cure the hematological compli-
cations related to this disease. In the absence of a fully matched re-
lated donor, the use of an unrelated donor is recommended but is
still associated with an increased rate of rejection and GVHD. Ob-
jective: Analyze the outcome of 33 pts with FA submitted to an
UBMT using CY+FLU+rATG in the conditioning regimen.
Patients and Methods: Period: 02/02 - 02/11, Age 5-18s (M:
10years) Sex: 17F/16M; Preparatory regimen: CY60mg/kg +
FLU125mg/m2 + rATG 4-6mg/kg; GVHD prophylaxis: Cyclo-
sporine and methotrexate. Stem cell source: bone marrow. All pts
and donors were HLA typed at least for low-resolution class I (locus
A, B, C) and high resolutionDRB1. 29pts were fully compatible (8/8)
and 4pts had one or two mismatches.
Results: 26 pts are alive between 8 months and 8ys days after BMT
(M: 2,7ys) with an overall survival (OS) of 79% in 3 years. 32 pts sur-
vived more than 28 days and were evaluated for engraftment. 3 pts
had only neutrophilic engraftment and all died between days +30
and +117 post BMT. One pt had primary graft failure (mismatch
in locus C) and received a 2nd UBMT (alive and well 4.8 ys after
UBMT). No late rejection occurred in this group of pts. Early com-
plications: mucositis grade III -IV: 75%. Moderate to severe arterial
hypertension: 70%. No pt developed severe hepatic sinusoidal syn-
drome. Hemorrhagic cystitis:7pts. Acute GVHD grade II-IV oc-
curred in 12/31 evaluable pts while chronic GVHD occurred in
11/26 evaluable pts (limited: 6pts; extensive: 5pts). Seven pts died be-
tween 20-117 days post UBMT (M: 50 days). Cumulative incidence
of TRM at 100 days was 18%. Causes of death were generally related
to infection (bacterial or fungal) or GVHD complications. Pts under
10 years had an excellent survival (94%) as well as those with fully
compatible donors (86%).
Conclusions:The results fromUBMT in FA have improved consid-
erably during the past few years. In this study, pts under the age of 10
had an excellent survival, equal to the one observed in pts with fully
matched related donors. Early referral, the use of conditioning reg-
imen containing fludarabine and the possibility of finding well
matched unrelated donors (65% of them found in the Brazilian reg-
istry) may have contributed for the success of this protocol.73
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR PATIENTS
WITH WISKOTT ALDRICH SYNDROME (WAS): ANALYSIS OF 36 CHIL-
DREN TRANSPLANTED IN A SINGLE INSTITUTION
Bonfim, C.1, Koliski, A.1, Ribeiro, L.1, Loth, G.1, Toassa Gomes, R.1,
Pasquini, R.1, Marinho, D.1, Kanaan, S.N.1, Cat, I.2, Zanis-Neto, J.1
1Federal University of Parana, Curitiba, PR, Brazil; 2Federal University
of Parana, Curitiba, PR, Brazil
WAS is a rare X-linked disease characterized by recurrent infec-
tions, eczema, thrombocytopeniawith small platelets andan increased
predisposition to autoimmunity and lymphoid malignancies. HSCT
is the only treatment with the possibility of cure.
Objective: Retrospective analysis of 36pts with WAS submitted to
HSCT at a single institution.
Patients andMethods: 36 boys; age: 0.9-14 ys (M: 2 ys), period: 04/
1992 05/2011. The majority of pts had severe manifestations of the
S230 Oral Presentationsdisease (score 3, 4 or 5). Type of donor: Related: 8pts (siblings: 5pts
and other related:3pts), Unrelated: 28pts. Source of stem cells: bone
marrow (BM): 12pts and umbilical cord blood (UCB):24pts (com-
patibility 6 / 6: 2pts, 5 / 6: 16pts, 4 / 6: 6pts). Conditioning: Cyclo-
phosphamide120-200mg/kg + Oral Busulfan16-20mg/kg +/- rATG.
Most pts received cyclosporine andmethotrexate as GVHDprophy-
laxis.
Results: 28pts is alive and well between 6 months and 17 ys after
HSCT (M:4,5ys) with an overall survival(OS) of 80,3% at 5ys.
35pts survived more than 28 days and were evaluable for engraft-
ment. Three pts had no engraftment (all received UCB).One pt
died onD+34 with pulmonary aspergillosis and the other two under-
went a 2nd UCBT. One is alive and well 7 years after transplant.
Nine of 32 evaluable pts developed an acute-GVHD, grades II-IV
(grade III-IV: 2pts). Eight of 31 evaluable pts developed C-GVHD
(extensive in 3pts). There was no significant difference in OS in
the univariate or multivariate analysis in relation to age less than
or greater than 5 years (76% vs. 82%), type of donor, related or un-
related (87.5% vs. 75%), source of stem cells, bone marrow or cord
blood (91.7% vs. 70,8%), presence or absence of acute-GVHD (78%
vs 92%); or Chronic GVHD (75% vs 91%). Eight pts died between
21 to 1832 days post HSCT (M: 137 days), most deaths occurred
during the first year of transplant (6pts) and were related to viral in-
fections (4pts), fungal (1pt) and GVHD associated with bacterial in-
fections (3pts). The cumulative incidence of TRM at 100 days was
8% and at 1 year was of 17%. Chemotherapy was well tolerated,
but reactivation/acquisition of viral infections (mainly RSV) during
the period of neutropenia contributed to the early death in some pts.
Conclusions: Despite the small number of pts this experince shows
an excellent survival for pts transplanted for WAS. Infections com-
plications (viral or fungal) are frequent and must be detected quickly
and treated aggressively.74
EFFECTS OF BODY MASS INDEX (BMI) IN CHILDREN UNDERGOING AL-
LOGENEIC BONEMARROWTRANSPLANT (BMT) FOR HEMATOLOGIC MA-
LIGNANCIES
Aplenc, R.1, Pasquini, M.C.2, Zhang,M.-J.2, Zhu, X.2, McCarthy, P.L.3,
Ho, V.T.4, Cooke, K.R.5, Sung, L.6, Bunin, N.J.1 1Children’s Hospital of
Philadelphia; 2CIBMTR, Medical College of Wisconsin; 3Roswell Park
Cancer Institute; 4Dana-Farber Cancer Institute; 5University Hospitals
Case Medical Center; 6The Hospital for Sick Children
The rising incidence of pediatric obesity may significantly impact
BMT outcomes for malignant diseases, as has been demonstrated in
increased mortality in children undergoing BMT for aplastic ane-
mia. Obesity may influence chemotherapy dosing and transplant re-
lated mortality (TRM). We analyzed 3,687 children ages 2-18, who
received BMT for treatment of hematologic malignancies using ei-
ther busulfan/cyclophosphamide (BuCy, N 5 1,196) or Cy/total
body irradiation-based (CyTBI, N 5 2,495) conditioning, between
1990 and 2007. Recipients were classified according to age-adjusted
BMI percentiles as underweight (\5% [UW], n5 282), at risk of un-
derweight (6-25% [RUW], n 5 509), normal (26-75%,[NW] n 5
1469), at risk of overweight (76-95% [ROW], n 5 987) and obese
(.95%, [OB] n 5 444). Total doses of chemotherapy administered
to patients in the ROW and OB groups were divided by actual and
ideal body weight to estimate dose adjustment practices. Median
age (10-13 y) and race were similar in all groups; OB group had
higher number of patients with acute lymphocytic leukemia (58%),
with early disease (52%), unrelated donor recipients (56%) and
from a U.S. center (61%). The table below summarizes adjusted
probabilities according to BMI groups.Multivariate analysis demon-
strated a higher TRM in the OB group (RR 1.32, p 5 0.0075) com-
pared to NW. Conversely, patients in the OB group had decreased
risk of relapse (RR 0.72, p 5 0.0037) compared to NW. There was
no significant impact of UW and RUW compared to NW in any
outcomes, and no differences in relapse-free and overall survival ac-
cording to BMI groups. Chemotherapy adjustment assessment dem-
onstrated that among 1,061 patients with available dose information,
171 (16%) had probable dose adjustment for conditioning. Obesity
was associated with higher TRM and lower relapse in children
with hematologic malignancies, likely related to higher intensity
conditioning, as doses were most often calculated based on actualweight. Additionally, patients with low BMI experienced similar out-
comes compared to patients with NW.
Table.
Outcomes UW RUW NW ROW OB
@ 3 years (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) p-valueN 282 509 1467 986 443
TRM 18 (13-22) 19 (16-22) 21 (18-22) 22 (20-25) 28 (24-32) 0.0034
Relapse 33 (28-39) 33 (29-37) 29 (26-31) 25 (23-28) 21 (17-25) <0.0001
RFS 48 (42-54) 48 (44-53) 50 (48-53) 52 (49-56) 51 (47-56) 0.54
OS 55 (49-61) 57 (52-61) 58 (56-61) 58 (55-61) 56 (52-61) 0.81Abbreviations: CI, confidence interval; NW, normal weight; OB, obese;
OS, Overall Survival; RFS, relapse free survival; ROW, risk of over-
weight; RUW, risk of underweight; UW, underweight
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SINGLE CENTER EXPERIENCE OF THIOTEPA, TREOSULPHAN & FLUDAR-
ABINE BASED REGIMEN IN THALASSEMIA MAJOR
Choudhary, D.1, Katewa, S.2, Kharya, G.1, Anjan, M.1, Setia, R.1 1BLK
Super Speciality Hospital, New Delhi, Delhi, India; 2Hospital for Sick
Children, Toronto, ON, Canada
The only curative treatment for Thalassemia major (TM) is allo-
genic bone marrow transplantation. The most commonly used con-
ditioning regimen is Busulphan, Cyclophosphamide and Anti
thymocyte globulin. This has high regimen related toxicities
(RRT). To minimize RRT, especially in high risk TM we studied
new conditioning regimen in prospectivemanner. Between February
2010 - September 2011, seventeen children with b-Thalassemia ma-
jor underwent Allogenic Bone Marrow Transplant at BLK Super
Speciality Hospital. The median age was 12 years. (Range 2-16 yrs.).
There were nine males & eight females, four patients belonged to
Pesaro class II and 13 were class III. All patients received condition-
ing with Thiotepa 8 mg/kg on D -6, Treosulphan 14 gm/m2/day
from D-5 to D-3 & Fludarabine 40 mg/m2/day from D-5 to D -2.
Sixteen children were transplanted with bone marrow graft from
HLA identical siblings (6/6 antigen) and one patient received bone
marrow graft from mother (5/6 antigen). Mean cell doses given
were: 6.36 106 cells /kg BW for CD34+ cells (Range 2.06 – 14.02
 106/kg) and 7.84  10 8/kg /BW for mononuclear cells (Range
2.9- 17.5 108/kg). Two patients had ABO major mismatch, 4 had
minor mismatch and 1 had bidirectional mismatch. Cyclosporine
& Methotrexate was used as GVHD prophylaxis. No patient devel-
oped grade III - IVGVHD.None of them requiredTPNor parental
analgesia. Sixteen out of seventeen patients achieved donor engraft-
ment.Median neutrophil engraftment was achieved onD+15 (Range
11 – 17 day) and median platelet engraftment was achieved on D+21
(Range 9 to 34 days). One patient developed grade II gut GVHD.
One patient expired on D+6 due to neutropenic enterocolitis, sepsis
and intracranial hemorrhage.
Median follow-up period was 12 months (Range 1 -20 mo). Till
last follow up, all the patients who achieved engraftment are alive
and transfusion independent.
Conclusion: Thiotepa, Treosulphan & Fludarabine based regimen
has acceptable toxicities with stable donor engraftment.
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UNRELATED CORD BLOOD TRANSPLANT (UCBT) IS ASSOCIATED LOW
RATES OF LONGTERM, PERSISTENT GRAFT VERSUS HOST DISEASE
(GVHD)
Craddock, J.A., Alsultan, A., Quinones, R.R., Keating, A., Hild, E.,
Benkhalil, N., Law, D., Peltz, A., Nuechterlein, B., Drake, K.,
Smolik, S., Giller, R.H. Childrens Hospital Colorado/University of Colo-
rado School of Medicine, Aurora, CO
Reduced rates of acute and chronic GVHD make unrelated cord
blood an attractive stem cell source. Adult marrow and PBSC from
unrelated donors are associated with higher rates of GVHD, persis-
tence or progression of GVHDmanifestations, need for chronic im-
munosuppressive therapies, reduced quality of life, infection, organ
toxicities, and decreased overall survival (OS). In contrast, recent
analyses from our center and others have indicated that GVHD
following UCBT does not adversely impact OS (BMT 2011,
46:668-675). To better understand the longterm outcomes of
